Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus VEETIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus VEETIDS.
LAROTID vs VEETIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic